Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been given an average rating of “Moderate Buy” by the five research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $11.40.

A number of equities analysts have weighed in on the company. Maxim Group lowered their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 8th. B. Riley lowered Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th. Finally, HC Wainwright lowered their price objective on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Marshall Wace LLP increased its holdings in Actinium Pharmaceuticals by 67.9% during the 2nd quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after purchasing an additional 103,557 shares during the period. Vanguard Group Inc. increased its holdings in Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the period. Virtu Financial LLC increased its holdings in Actinium Pharmaceuticals by 319.2% during the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after purchasing an additional 62,459 shares during the period. Squarepoint Ops LLC purchased a new stake in Actinium Pharmaceuticals during the 2nd quarter worth about $356,000. Finally, Renaissance Technologies LLC purchased a new stake in Actinium Pharmaceuticals during the 2nd quarter worth about $142,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM opened at $1.72 on Friday. The firm has a 50 day simple moving average of $1.86. The firm has a market capitalization of $51.23 million, a price-to-earnings ratio of -1.01 and a beta of 0.14. Actinium Pharmaceuticals has a 12 month low of $1.33 and a 12 month high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. On average, analysts anticipate that Actinium Pharmaceuticals will post -1.38 earnings per share for the current fiscal year.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).